Angioflux® (Angioflux®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceSulodexideSulodexide
Similar drugsTo uncover
  • Angioflux®
    capsules inwards 
    Mitim Sr.L.     Italy
  • Angioflux®
    solution w / m in / in 
    Mitim Sr.L.     Italy
  • Wessel Doué F
    capsules inwards 
    Alfa Wassermann SpA     Italy
  • Wessel Doué F
    solution w / m in / in 
    Alfa Wassermann SpA     Italy
    • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:

    Each ampoule (2 ml) contains:

    Active ingredient: sulodexide - 600 JIE *;

    Auxiliary Ingredients: sodium chloride, water for injection * - lipoprotein lipase unit.

    Description:Transparent solution from light yellow to yellow.
    Pharmacotherapeutic group:Anticoagulant means of direct action
    ATX: & nbsp

       

    Pharmacodynamics:

    pharmachologic effect

    Active active ingredient of the preparation Angioflux® - sulodexide - natural product, a natural mixture of glucosaminoglycans, consisting of a high-speed heparin-like fraction (80%) and dermatan sulfate (20%), obtained by enzymatic extraction from the mucous membrane of the small intestine of pigs. The mechanism of action of sulodexide is due to the interaction of both fractions:

    - a high-speed heparin-like fraction has an affinity for antithrombin III (ATIII);

    - dermatan sulfate has an affinity for the cofactor Heparin II (KG II).

    Pharmacodynamics

    Angioflux® has antithrombotic, profibrinolytic, angioprotective and anticoagulant effects.

    The mechanism of antithrombotic action is associated with the suppression of activated Ha and Pa clotting factor, increased synthesis and secretion of prostacyclin, a decrease in the concentration of fibrinogen in the blood plasma.

    The prophyllinolytic effect of the drug is due to an increase in the concentration of the tissue plasminogen activator (TAP) in the blood vessel and the decrease in the content of the inhibitor of tissue plasminogen activator (ITAP) in the blood. The mechanism of angioprotective action is associated with the restoration of the structural and functional integrity of the vascular endothelial cells, restoring the normal density of the negative electric charge of the pores of the basal membrane of the vessels. The drug normalizes the rheological properties of blood by reducing the concentration of triglycerides, as it stimulates the lipolytic enzyme - lipoprotein lipase, hydrolysing triglycerides. The efficacy of Angioflux® in diabetic nephropathy is determined by itsthe ability to reduce the thickness of the basal membrane and the production of the extracellular matrix by reducing the proliferation of mesangium cells.

    Pharmacokinetics:With parenteral administration sulodexide quickly enters a large circle of circulation and is distributed to organs and tissues. 90% of sulodexide is absorbed into the vascular endothelium and absorbed into the small intestine. The time to reach the maximum concentration for parenteral administration is 5-15 minutes. Unlike low molecular weight and unfractionated heparins sulodexide It does not desulfate, which leads to a decrease in antithrombotic activity and significantly accelerates elimination from the body. Metabolized in the liver and excreted by the kidneys 4 hours after the injection. During the first 24 hours, 50% of the sulodexide is excreted in the urine, and after 67 hours, 67%.
    Indications:

    Angiopathy with an increased risk of thrombosis.

    Microangiopathy (nephropathy, retinopathy, neuropathy).

    Macroangiopathy in diabetes mellitus.

    Contraindications:

    Hypersensitivity to sulodexide or one of the auxiliary components of the drug; hemorrhagic diathesis and other diseases accompanied by hypocoagulation; pregnancy I trimester.

    You should not prescribe Angioflux® to patients with hypersensitivity to heparin and preparations of a similar type, since the molecular structure of sulodexide is similar to that of heparin.

    Carefully:Patients on a salt-free diet (due to the presence of sodium).
    Pregnancy and lactation:In the II and III trimester of pregnancy and during breastfeeding, the medicinal product can be used only in cases of extreme necessity, if the benefit to the mother exceeds the potential risk to the fetus and the baby, and under the supervision of the doctor.
    Dosing and Administration:

    Intravenous (bolus or drip) or intramuscularly, 2 ml (1 ampoule) per day.

    For intravenous drip, the preparation is first diluted in 150-200 ml of 0.9% sodium chloride solution.

    Treatment is recommended starting with parenteral administration of the drug for 15-20 days, after which they switch to capsules for 30-40 days. The full course of treatment is carried out 2 times a year.

    The duration of the course and the dose of the drug may vary depending on the results of the clinical and diagnostic examination of the patient.

    Side effects:Soreness, burning sensation and bruising at the injection site; allergic reactions (skin rash).
    Overdose:

    Symptoms: bleeding.

    In case of an overdose, the drug is canceled and symptomatic therapy is administered.

    Interaction:Strengthens the anticoagulant effect of heparin, indirect anticoagulants and antiplatelet agents; If possible, avoid their simultaneous application.
    Special instructions:If it is necessary to simultaneously take anticoagulants and antiplatelet agents, periodic monitoring of blood clotting parameters is recommended.
    Effect on the ability to drive transp. cf. and fur:Angioflux® does not affect the ability to drive vehicles or work with machinery.
    Form release / dosage:
    Solution for intravenous and intramuscular injection, 600 JIE / 2 ml.
    Packaging:

    For 2 ml in dark glass ampoules with a ring of fracture.

    5 ampoules in the outline of the cell.

    2 contour mesh packages with instructions for use are placed in a pack of cardboard.

    Storage conditions:At a temperature of no higher than 30 ° C. Keep out of the reach of children!
    Shelf life:
    3 years. Do not use after expiration date
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-006241/10
    Date of registration:01.07.2010
    Expiration Date:Unlimited
    The owner of the registration certificate:Mitim Sr.L.Mitim Sr.L. Italy
    Manufacturer: & nbsp
    Representation: & nbspFARMAKOR PRODUCTION LLC FARMAKOR PRODUCTION LLC Russia
    Information update date: & nbsp04.09.2017
    Illustrated instructions
      Instructions
      Up